Traditional Chinese Medicine Targeting Sarcoma Virus Oncogene-related Diseases

Yiying Wang; Xiaoyu Wang; Kexin Su; Yifu Yang

doi:10.2174/1568009623666230426093244

Traditional Chinese Medicine Targeting Sarcoma Virus Oncogene-related Diseases

Curr Cancer Drug Targets. 2023;23(10):751-763. doi: 10.2174/1568009623666230426093244.

Authors

Yiying Wang¹, Xiaoyu Wang^{1

2}, Kexin Su¹, Yifu Yang¹

Affiliations

¹ Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
² State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

PMID: 37170983
DOI: 10.2174/1568009623666230426093244

Abstract

The sarcoma virus oncogene (Src) tyrosine kinase, a nonreceptor protein-tyrosine kinase, plays a crucial role in cell survival, migration, differentiation and proliferation. The study of Src has developed considerably since it was first discovered as a proto-oncogene. Src has also been associated with inflammation and bone-related diseases. Src inhibitors (bosutinib, ponatinib, dasatinib, and vandetanib) have been put into clinical use. However, their side effects and cardiovascular toxicity may be a concern. There is an urgent need to explore new Src inhibitors. Traditional Chinese medicine (TCM), which has a vast history, can provide a broad resource base. Many natural compounds and TCM extracts have the potential for anti-Src treatment. This article describes the natural compounds and extracts from TCM.

Keywords: c-Src; cancer; inflammation; natural compounds; osteoblast; traditional chinese medicine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Medicine, Chinese Traditional*
Oncogenes
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Sarcoma* / drug therapy
src-Family Kinases

Substances

Protein Kinase Inhibitors
src-Family Kinases